Product Code: IRTNTR31900
About this market
Technavio's Interleukin inhibitors market analysis considers sales from Interleukin-23 inhibitors, Interleukin-17 inhibitors, Interleukin-6 inhibitors, and other Interleukin inhibitors. Our analysis also considers the sales of Interleukin inhibitors in Asia, Europe, North America, and ROW. In 2018, the Interleukin-23 inhibitors segment had a significant market share, and this trend is expected to continue over the forecast period. Factors such as the high prevalence of psoriasis and improved R&D on Interleukin-23 inhibitors will help in the growth of Interleukin-23 inhibitors segment and maintain its market position. Also, our global Interleukin inhibitors market report looks at factors such as high target affinity and specificity of Interleukin inhibitors, recent approvals and robust pipeline, and presence of reimbursement and patient assistance program. However, availability of substitutes, product withdrawals and failure of clinical trials, and adverse side effects and high cost of Interleukin inhibitors may hamper the growth of the Interleukin inhibitors industry over the forecast period.
Overview
High target affinity and specificity of Interleukin inhibitors
Interleukin inhibitors are target specific and work directly in Interleukin receptors. These drugs are highly effective in the treatment of autoimmune diseases such as psoriasis, rheumatoid arthritis, and Crohn's disease. Higher patient adherence to these drugs because of their higher affinity and specificity. The advances in the R&D Interleukin drugs and clinical trials for late-stage molecules is expected to lead the expansion of the global Interleukin inhibitors market at a CAGR of almost 13% during the forecast period.
Increasing awareness about autoimmune diseases
The major focus of the awareness programs is to educate people about the symptoms of various arthritis indications, cause of the diseases, risk factors that cause inflammation, availability of various treatments and preventive measures that can be taken to control the disease. These awareness campaigns are expected to have a positive impact on the overall market growth.
For the detailed list of factors that will drive the global Interleukin inhibitors market during the forecast period 2019-2023, view our report.
Competitive Landscape
With the presence of several major players, the global Interleukin inhibitors market is fragmented. Technavio's robust vendor analysis is designed to help clients improve their market position, and in line with this, this report provides a detailed analysis of several leading Interleukin inhibitors manufacturers, that include Eli Lilly and Co., F. Hoffmann-La Roche Ltd., Johnson & Johnson Services Inc., Novartis AG, Regeneron Pharmaceuticals Inc.
Also, the Interleukin inhibitors analysis report includes information on upcoming trends and challenges that will influence market growth. This is to help companies strategize and leverage on all forthcoming growth opportunities.
TABLE OF CONTENTS
PART 01: EXECUTIVE SUMMARY
PART 02: SCOPE OF THE REPORT
- 2.1 Preface
- 2.2 Preface
- 2.3 Currency conversion rates for US$
PART 03: MARKET LANDSCAPE
- Market ecosystem
- Market characteristics
- Market segmentation analysis
PART 04: MARKET SIZING
- Market definition
- Market sizing 2018
- Market size and forecast 2018-2023
PART 05: FIVE FORCES ANALYSIS
- Bargaining power of buyers
- Bargaining power of suppliers
- Threat of new entrants
- Threat of substitutes
- Threat of rivalry
- Market condition
PART 06: MARKET SEGMENTATION BY PRODUCT
- Market segmentation by product
- Comparison by product
- Interleukin-23 inhibitors - Market size and forecast 2018-2023
- Interleukin-17 inhibitors - Market size and forecast 2018-2023
- Interleukin-6 inhibitors - Market size and forecast 2018-2023
- Other Interleukin inhibitors - Market size and forecast 2018-2023
- Market opportunity by product
PART 07: CUSTOMER LANDSCAPE
PART 08: GEOGRAPHIC LANDSCAPE
- Geographic segmentation
- Geographic comparison
- North America - Market size and forecast 2018-2023
- Europe - Market size and forecast 2018-2023
- Asia - Market size and forecast 2018-2023
- ROW - Market size and forecast 2018-2023
- Key leading countries
- Market opportunity
PART 09: DECISION FRAMEWORK
PART 10: DRIVERS AND CHALLENGES
- Market drivers
- Market challenges
PART 11: MARKET TRENDS
- Increasing awareness about autoimmune diseases
- Strategic alliances
- Introduction of biosimilars
PART 12: VENDOR LANDSCAPE
- Overview
- Landscape disruption
- Competitive scenario
PART 13: VENDOR ANALYSIS
- Vendors covered
- Vendor classification
- Market positioning of vendors
- Eli Lilly and Co.
- F. Hoffmann-La Roche Ltd.
- Johnson & Johnson Services Inc.
- Novartis AG
- Regeneron Pharmaceuticals Inc.
PART 14: APPENDIX
- Research methodology
- List of abbreviations
- Definition of market positioning of vendors
PART 15: EXPLORE TECHNAVIO
LIST OF EXHIBITS:
- Exhibit 01: Product overview
- Exhibit 02: Global pharmaceuticals market
- Exhibit 03: Segments of global pharmaceuticals market
- Exhibit 04: Market characteristics
- Exhibit 05: Market segments
- Exhibit 06: Market definition - Inclusions and exclusions checklist
- Exhibit 07: Market size 2018
- Exhibit 08: Global market: Size and forecast 2018-2023 ($ millions)
- Exhibit 09: Global market: Year-over-year growth 2019-2023 (%)
- Exhibit 10: Five forces analysis 2018
- Exhibit 11: Five forces analysis 2023
- Exhibit 12: Bargaining power of buyers
- Exhibit 13: Bargaining power of suppliers
- Exhibit 14: Threat of new entrants
- Exhibit 15: Threat of substitutes
- Exhibit 16: Threat of rivalry
- Exhibit 17: Market condition - Five forces 2018
- Exhibit 18: Product - Market share 2018-2023 (%)
- Exhibit 19: Comparison by product
- Exhibit 20: Interleukin-23 inhibitors - Market size and forecast 2018-2023 ($ millions)
- Exhibit 21: Interleukin-23 inhibitors - Year-over-year growth 2019-2023 (%)
- Exhibit 22: Interleukin-17 inhibitors - Market size and forecast 2018-2023 ($ millions)
- Exhibit 23: Interleukin-17 inhibitors - Year-over-year growth 2019-2023 (%)
- Exhibit 24: Interleukin-6 inhibitors - Market size and forecast 2018-2023 ($ millions)
- Exhibit 25: Interleukin-6 inhibitors - Year-over-year growth 2019-2023 (%)
- Exhibit 26: Other Interleukin inhibitors - Market size and forecast 2018-2023 ($ millions)
- Exhibit 27: Other Interleukin inhibitors - Year-over-year growth 2019-2023 (%)
- Exhibit 28: Market opportunity by product
- Exhibit 29: Customer landscape
- Exhibit 30: Market share by geography 2018-2023 (%)
- Exhibit 31: Geographic comparison
- Exhibit 32: North America - Market size and forecast 2018-2023 ($ millions)
- Exhibit 33: North America - Year-over-year growth 2019-2023 (%)
- Exhibit 34: Top 3 countries in North America
- Exhibit 35: Europe - Market size and forecast 2018-2023 ($ millions)
- Exhibit 36: Europe - Year-over-year growth 2019-2023 (%)
- Exhibit 37: Top 3 countries in Europe
- Exhibit 38: Asia - Market size and forecast 2018-2023 ($ millions)
- Exhibit 39: Asia - Year-over-year growth 2019-2023 (%)
- Exhibit 40: Top 3 countries in Asia
- Exhibit 41: ROW - Market size and forecast 2018-2023 ($ millions)
- Exhibit 42: ROW - Year-over-year growth 2019-2023 (%)
- Exhibit 43: Top 3 countries in ROW
- Exhibit 44: Key leading countries
- Exhibit 45: Market opportunity
- Exhibit 46: Recently approved Interleukin inhibitor molecules
- Exhibit 47: Some of the late-stage pipeline molecules
- Exhibit 48: Some of the available substitutes for Interleukin inhibitors
- Exhibit 49: Some of the serious side effects of Interleukin inhibitors are listed below:
- Exhibit 50: Impact of drivers and challenges
- Exhibit 51: Vendor landscape
- Exhibit 52: Landscape disruption
- Exhibit 53: Vendors covered
- Exhibit 54: Vendor classification
- Exhibit 55: Market positioning of vendors
- Exhibit 56: Eli Lilly and Co. - Vendor overview
- Exhibit 57: Eli Lilly and Co. - Product segments
- Exhibit 58: Eli Lilly and Co. - Organizational developments
- Exhibit 59: Eli Lilly and Co. - Geographic focus
- Exhibit 60: Eli Lilly and Co. - Segment focus
- Exhibit 61: Eli Lilly and Co. - Key offerings
- Exhibit 62: Eli Lilly and Co. - Key customers
- Exhibit 63: F. Hoffmann-La Roche Ltd. - Vendor overview
- Exhibit 64: F. Hoffmann-La Roche Ltd. - Business segments
- Exhibit 65: F. Hoffmann-La Roche Ltd. - Organizational developments
- Exhibit 66: F. Hoffmann-La Roche Ltd. - Geographic focus
- Exhibit 67: F. Hoffmann-La Roche Ltd. - Segment focus
- Exhibit 68: F. Hoffmann-La Roche Ltd. - Key offerings
- Exhibit 69: F. Hoffmann-La Roche Ltd. - Key customers
- Exhibit 70: Johnson & Johnson Services, Inc. - Vendor overview
- Exhibit 71: Johnson & Johnson Services, Inc. - Business segments
- Exhibit 72: Johnson & Johnson Services, Inc. - Organizational developments
- Exhibit 73: Johnson & Johnson Services, Inc. - Geographic focus
- Exhibit 74: Johnson & Johnson Services, Inc. - Segment focus
- Exhibit 75: Johnson & Johnson Services, Inc. - Key offerings
- Exhibit 76: Johnson & Johnson Services, Inc. - Key customers
- Exhibit 77: Novartis AG - Vendor overview
- Exhibit 78: Novartis AG - Business segments
- Exhibit 79: Novartis AG - Organizational developments
- Exhibit 80: Novartis AG - Geographic focus
- Exhibit 81: Novartis AG - Segment focus
- Exhibit 82: Novartis AG - Key offerings
- Exhibit 83: Novartis AG - Key customers
- Exhibit 84: Regeneron Pharmaceuticals Inc. - Vendor overview
- Exhibit 85: Regeneron Pharmaceuticals Inc. - Business segments
- Exhibit 86: Regeneron Pharmaceuticals Inc. - Organizational developments
- Exhibit 87: Regeneron Pharmaceuticals Inc. - Key offerings
- Exhibit 88: Regeneron Pharmaceuticals Inc. - Key customers
- Exhibit 89: Validation techniques employed for market sizing
- Exhibit 90: Definition of market positioning of vendors
